hexamethylenetetramine Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methenamine is an antibacterial agent for preventing recurrent urinary tract infection. It can be used as methenamine hippurate or methenamine mandelate preparations and is United States Food and Drug Administration-approved. Methenamine exerts its activity because it is hydrolyzed to formaldehyde in acid urine.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.1642

United States

$0.2893 - $2.4053
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,3,5,7-tetraazatricyclo[3.3.1.13,7]decane | 3m brand 1 of methenamine hippurate | 3m brand 2 of methenamine hippurate | e239 | hexamethylenamine | hexamethylenetetramine | hexamethylene tetramine | hexamethylene tetramine hippurate | hexamethylenetetramine hippurate | hexamethylenetetramine hippuric acid complex | hexamethylentetramin | hexamethylentetraminum | hexamine | hexamine hippurate | hexaminum | hiprex | hip-rex | hmt | hmta | metenamina | methenamin | methenamine | méthénamine | methenamine hippurate | methenaminum | united drug brand of methenamine hippurate | urex | uritone | urotractan | urotropin

Organizations (15)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (2)


 

Infections

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Dysuria (Phase 3)

Urinary Tract Infections ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue